Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Non Small Cell Lung Cancer (NSCLC)

This study is currently recruiting participants.

Verified by Istituto Clinico Humanitas, August 2009

First Received: September 30, 2008 Last Updated: August 28, 2009 History of Changes

Sponsor:	Istituto Clinico Humanitas
Information provided by:	Istituto Clinico Humanitas
ClinicalTrials.gov Identifier:	NCT00763607

Purpose

Aim of the study is to evaluated the role of IGF1R and p95HER2 on prognosis in radically resected non small cell lung cancer patients

The primary objective is to correlate the expression of IGF1R and p95HER2 with survival.

Condition	Intervention
Non Small Cell Lung Cancer	Genetic: Protein expression by immunohistochemistry and immunofluorescence

Study Type:	Observational
Study Design:	Cohort, Retrospective
Official Title:	Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Radically Resected Non Small Cell Lung Cancer

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lung Cancer

U.S. FDA Resources

Further study details as provided by Istituto Clinico Humanitas:

Primary Outcome Measures:

Association of different biomarkers with survival [ Time Frame: At the end of enrollment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Association of a specific biomarker with patient's characteristics [ Time Frame: At the end of enrollment ] [ Designated as safety issue: No ]

Biospecimen Retention: Samples With DNA

Biospecimen Description:

Paraffine embedded tumor sections

Estimated Enrollment:	454
Study Start Date:	November 2007
Estimated Study Completion Date:	December 2009
Primary Completion Date:	February 2008 (Final data collection date for primary outcome measure)

Groups/Cohorts	Assigned Interventions
1 Radically resected Non small cell lung cancer patients in stage I-III	Genetic: Protein expression by immunohistochemistry and immunofluorescence Protein expression by immunohistochemistry and immunofluorescence

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Radically resected non small cell lung cancer patients

Criteria

Inclusion Criteria:

Radically resected non small cell lung cancer patients with tumor tissue available

Exclusion Criteria:

Tumor tissue not available
Clinical data not available

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00763607

Contacts

Contact: Armando Santoro, MD	+39028224 ext 4080	armando.santoro@humanitas.it
Contact: Federico Cappuzzo, MD	+39028224 ext 4080	federico.cappuzzo@humanitas.it

Locations

Italy, Milan
Istituto Clinco Humanitas	Recruiting
Rozzano, Milan, Italy, 20089
Contact: Armando Santoro, MD +39028224 ext 4080 armando.santoro@humanitas.it
Contact: Federico Cappuzzo, MD +39028224 ext 4080 federico.cappuzzo@humanitas.it

Sponsors and Collaborators

Istituto Clinico Humanitas

Investigators

Principal Investigator:

Armando Santoro, MD

Istituto Clinico Humanitas

More Information

No publications provided

Responsible Party:	Istituto Clinico Humanitas ( Armando Santoro, MD )
Study ID Numbers:	ONC/OSS-02/2007
Study First Received:	September 30, 2008
Last Updated:	August 28, 2009
ClinicalTrials.gov Identifier:	NCT00763607 History of Changes
Health Authority:	Italy: Ministry of Health

Keywords provided by Istituto Clinico Humanitas:

non small cell lung cancer patients

Additional relevant MeSH terms:

Thoracic Neoplasms
Respiratory Tract Neoplasms
Neoplasms
Neoplasms by Site
Neoplasms by Histologic Type
Respiratory Tract Diseases

Lung Neoplasms
Lung Diseases
Carcinoma, Non-Small-Cell Lung
Neoplasms, Glandular and Epithelial
Carcinoma

ClinicalTrials.gov processed this record on February 08, 2010